ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials.
CEO
Mr. Jaume Pons, PhDGlassdoor
Employee Ratings-0.10000000149011612 / 50 reviews
-10% recommend to a friend
$340M
Market Cap • 02/06/20232020
(3 years ago)
2020
(3 years ago)
South San Francisco
Headquarters • California58
Employees • 2022Valuation
Company FinancialsValuation Indicators
Valuation Indicators| Year | Equity | Revenue | EBITDA | Fin. Res. | Net Inc. | Net Mar. | ROE | Cash | Debt | N.D. / EBITDA | OCF | CAPEX | FCF | Free | Div. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/23 TTM | 240 | 0 | -132 | 6 | -129 | L | L | 228 | 10 | L | -96 | -2 | 10 | -98 | 0 |
The values above are represented in USD and the scale is in millions—10.000 is the equivalent of 10 billions. L inside the table means Loss.